What is the armodafinil dosage?
| Item | Label |
|---|---|
| Tablet strengths | 50, 150, 200 and 250 mg1 |
| Obstructive sleep apnea or narcolepsy | 150 mg to 250 mg orally once a day as a single dose in the morning1 |
| Shift work disorder | 150 mg orally once a day, approximately 1 hour before the work shift1 |
The Nuvigil label gives 150 mg to 250 mg once a day in the morning for sleep apnea or narcolepsy and 150 mg once a day about 1 hour before the work shift for shift work disorder.1
Tablet strengths and labelled doses
The table is set at the top of the page
The label names 250 mg/day as the maximum recommended human dose.1 In sleep apnea it says doses up to 250 mg/day, given as a single dose, were well tolerated, with no consistent evidence of added benefit over 150 mg/day.1 For severe hepatic impairment the label calls for a reduced dosage, and for geriatric patients it asks that lower doses and close monitoring be considered.1 It gives no number for either.
What the trials used
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Roth 2006, sleep apnea | 150 mg/d or 250 mg/d or placebo, once daily2 | 395 nCPAP-adherent adults with residual sleepiness: 133, 131 and 131 per arm2 | 12 weeks2 |
| Harsh 2006, narcolepsy | 150 mg, 250 mg or placebo, once daily3 | 196 adults: 65, 67 and 64 per arm3 | 12 weeks3 |
| Czeisler 2009, shift work disorder | 150 mg or placebo, 30 to 60 minutes before each night shift4 | 254 night-shift workers4 | 12 weeks4 |
In Darwish 2010, an open-label crossover pharmacokinetic study in 42 patients with treated sleep apnea, multiple-dose armodafinil was 100 mg once daily on days 1 and 2, then 200 mg once daily on days 3 through 10.5
How armodafinil is taken
The label's dose is taken orally once a day: as a single dose in the morning for sleep apnea or narcolepsy, and about 1 hour before the work shift for shift work disorder.1 The Medication Guide says Nuvigil too close to bedtime may make it harder to go to sleep.1 Peak levels come about 2 hours after a fasted dose, and food may delay this by 2-4 hours.1 Steady state is reached within 7 days, at 1.8 times the exposure after a single dose.1 Darwish 2009, a pooled analysis of three single-dose studies in healthy adults, found a mean terminal half-life of about 13 hours for armodafinil.6 In Darwish 2010, in 42 patients with treated sleep apnea, the mean half-life of armodafinil was 16.5 (SD 4.44) hours.5
Storage
The label says to store tablets at 20o - 25o C (68o - 77o F).1
Mixing, syringe marks and logged use
The Nuvigil label lists armodafinil only as tablets, so there is no concentration, water volume or syringe mark to work out.1 Too few people logged armodafinil in Milligram for a share to be printed at the 50-person floor.
- Units and dosingUnits and syringe marks for other compounds.
- ArmodafinilHalf-life, trial results and label status.
- Cognitive and sleep peptidesOther compounds for cognition and sleep.
- Noopept dosageAnother cognitive compound.
- Bromantane dosageAnother cognitive compound.
- How to take methylene blueAnother oral compound.
Frequently asked questions
Can you take armodafinil with food?
The Medication Guide says Nuvigil can be taken with or without food.1
Is armodafinil labelled for ADHD or studying?
The label's indication is excessive sleepiness in adults with sleep apnea, narcolepsy or shift work disorder, and it lists no other condition.1 A review of armodafinil for adult ADHD says trials are still needed before it can be a therapeutic alternative.8 The pack found no armodafinil ADHD trial and no student trial. The same 2024 review reports several studies in healthy adult men in which armodafinil 250 mg improved alertness during sleep deprivation compared with placebo.8
Does armodafinil have cycles or breaks?
The label has no cycling advice and says abrupt cessation or dose reduction after chronic use can cause withdrawal symptoms.1
References
- Cephalon, LLC (DailyMed). These highlights do not include all the information needed to use NUVIGIL safely and effectively. See full prescribing information for NUVIGIL. NUVIGIL ® (armodafinil) tablets, for oral use, C-IV Initial U.S. Approval: 2007. 2022. dailymed.nlm.nih.gov
- PubMed. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. 2006. pubmed.ncbi.nlm.nih.gov
- PubMed. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. 2006. pubmed.ncbi.nlm.nih.gov
- PMC. Armodafinil for Treatment of Excessive Sleepiness Associated With Shift Work Disorder: A Randomized Controlled Study. pmc.ncbi.nlm.nih.gov
- PubMed. Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. 2010. pubmed.ncbi.nlm.nih.gov
- PubMed. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. 2009. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT01305408: Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder. 2015. clinicaltrials.gov
- PMC. Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review. 2024. pmc.ncbi.nlm.nih.gov